Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
life sciences
national blog main
san diego blog main
biotech
boston
dyne therapeutics
myotonic dystrophy type 1
national top stories
new york blog main
rare disease drugs
san diego top stories
akcea therapeutics
anylam pharmaceuticals
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
biotech ipos
bluebird bio
cardiomyopathy
drugs
duchenne muscular dystrophy
facioscapulohumeral muscular dystrophy
fda
gene therapy
inotersen
joshua brumm
kaleido biosciences
metacrine
muscular dystrophy
neuropathy
new york
new york top stories
nonalcoholic steatohepatitis
onpattro
patisiran
pfizer
What
medicines
4
×
rare
4
×
drug
genetic
ago
dyne
ipo
muscle
therapeutics
agency
akcea
alnylam
amyloidosis
approved
astrazeneca
attr
available
battle
benefits
biotechs
blood
brings
clots
cnet
company
considering
covid
data
debilitating
developing
disease
diseases
disorders
dyne’s
early
effect
effects
european
expected
experimental
Language
unset
Current search:
rare
×
medicines
×
@cnet.com
3 years ago
AstraZeneca vaccine: Blood clots should be listed as 'very rare' side effect, says EU regulator - CNET
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
